证券代码：688238 证券简称：和元生物 公告编号：2026-006 和元生物技术（上海）股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以和元生物技术（上海）股份有限公司（以下简称"公司"）2025 年年度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 26,766.34 | 24,814.92 | 7.86 | | 营业利润 | -21,800.20 | -31,045.08 | 不适用 | | 利润总额 | -21,832.44 | -31,262.71 | 不适用 | | 归属于母公司所有者的净利润 | -22,071.57 | -32,181.30 | 不适用 | | 归属于母公司所有 ...

2月25日，和辉光电大宗交易成交1350万股，成交额3523.5万元，占当日总成交额的17.59%，成交价2.61元，较市场收盘价2.63元折价0.76%。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-25 | 和辉光电 | 688238 | 2.61 3523.5 | 1350 | 机构专用 | 国泰海通证券股份 有限公司上海静安 区北京商路 区北京商路 | | ...

Summary of Key Points Core Viewpoint The article discusses the recent developments in China's mother fund industry, highlighting the total management scale of 1161.5 billion yuan, with investments spanning various sectors such as artificial intelligence, new production capacity, and integrated circuits. The article provides insights into fund management recruitment, fund establishment, and LP contributions across different provinces. Fund Management Recruitment - Hebei Province is seeking GP for its Science and Technology Investment Guidance Fund to support strategic and future industries [7] - Sichuan Province is recruiting GP for the Cultural Tourism New Quality Productivity Industry Fund [15] - Chongqing is looking for GP for the Rongchang Mother Fund [17] - Gansu Province is inviting GP for the Jiuquan Science and Technology and Industry Development Fund [20] - Other provinces such as Guangdong, Yunnan, Jiangsu, and Hubei are also actively recruiting GPs for various funds [5][6][43] Fund Establishment - The Jiangsu Super Mother Fund has signed agreements totaling 691 billion yuan, focusing on strategic emerging industries [33][36] - The Yunnan Advanced Manufacturing Equity Investment Mother Fund aims to enhance industrial competitiveness and promote high-quality development [28] - The Shanghai Integrated Circuit Industry Investment Fund has increased its capital to 60.3 billion yuan, marking a significant growth of approximately 1038% [55] LP Contributions - Watson Bio has initiated the establishment of the Yunnan Chuangwo Biological Industry Investment Fund with a target size of 1 billion yuan, contributing 450 million yuan [44] - Jinzhitech plans to invest 240 million yuan to establish an industrial fund in collaboration with local partners [46] - The establishment of the Hohhot Zhongjin Qixin Equity Investment Fund has been announced, with a total investment of 10 billion yuan [51] Other Developments - The establishment of the Ezhou Intelligent Development Equity Investment Fund with a total scale of 30 billion yuan aims to support the AI industry [43] - The Jiangsu Province has successfully registered two industry mother funds with a total scale of 6.5 billion yuan, focusing on smart manufacturing and industrial development [41]

股票简称：和元生物 股票代码：688238 2026 年第一次临时股东会 会议资料 和元生物技术（上海）股份有限公司 OBiO Technology (Shanghai) Corp., Ltd. 2026 年 2 月 和元生物技术（上海）股份有限公司 2026 年第一次临时股东会会议资料 和元生物技术（上海）股份有限公司 2026 年第一次临时股东会会议资料目录 | 2026 年第一次临时股东会会议须知 2 | | | --- | --- | | 2026 年第一次临时股东会会议议程 4 | | | 2026 年第一次临时股东会会议议案 6 | | | 议案一、《关于参与设立产业并购基金暨关联交易的议案》 | 7 | | 议案二、《关于变更公司名称、修订<公司章程>并办理工商变更登记的议案》 | 9 | 1 和元生物技术（上海）股份有限公司 2026 年第一次临时股东会会议资料 和元生物技术（上海）股份有限公司 2026 年第一次临时股东会会议须知 为维护广大投资者的合法权益，确保和元生物技术（上海）股份有限公司（以 下简称"公司"或"和元生物"）股东会的正常秩序和议事效率，保障股东在本 次股东会期间依法行使 ...

Core Viewpoint - The article discusses the establishment of a new 500 million RMB industrial merger fund by He Yuan Biotechnology, highlighting the growing trend of merger funds in the Chinese market and the supportive policies driving this growth [2][3][8]. Group 1: Fund Establishment - He Yuan Biotechnology announced its plan to co-establish the He Yuan Hongsheng Industrial Investment Fund with Shanghai Hongsheng Junhao Equity Investment Fund Management Co., Ltd. and other partners, with a total fund size of 500 million RMB [5]. - He Yuan Biotechnology will contribute up to 100 million RMB as a limited partner (LP), accounting for 20% of the fund, while the general partners will contribute 5 million RMB, representing 1% [5]. - The fund's duration is set for 8 years, with the first 4 years designated for investment and the latter 4 years for exit [5]. Group 2: Investment Focus - The fund will focus on the cell and gene therapy (CGT) industry chain and related upstream and downstream fields, aiming to provide systematic and efficient tools for industrial integration [6]. - He Yuan Biotechnology aims to leverage Hongsheng Junhao's resources and advantages in equity investment to create a "dedicated strategic platform" around its industrial ecosystem [6]. Group 3: Market Trends - The establishment of this fund reflects a broader trend in the merger fund industry, which has seen significant growth since 2025, driven by supportive policies such as the "New National Nine Articles" and "Merger Six Articles" [8]. - In 2025, 305 listed companies participated in the establishment of 321 industrial merger funds, with a total fundraising scale of approximately 297.51 billion RMB, showing a notable increase from 2024 [8]. - The merger and acquisition (M&A) market is experiencing a surge, with significant transactions across various sectors, including consumer goods, manufacturing, resources, and biomedicine [9]. Group 4: Policy Support - The Chinese government is enhancing support for the merger fund sector, with plans to establish a national-level merger fund and promote innovation and entrepreneurship [10]. - New merger funds are increasingly concentrated in strategic sectors such as advanced manufacturing, healthcare, artificial intelligence, automotive, new materials, and semiconductors, indicating their role in implementing national industrial policies [10]. - In 2025, the transaction volume of China's M&A market exceeded 400 billion USD, marking a 47% year-on-year increase, with expectations for continued activity in high-tech and new energy sectors in 2026 [10].

Group 1 - The core point of the article is that Heyuan Biotechnology (Shanghai) Co., Ltd. has invested 3.35 million RMB to establish Anxing Zhenghe (Changsha) Biotechnology Co., Ltd., holding a 67% stake in the new company [1] - Anxing Zhenghe (Changsha) Biotechnology Co., Ltd. was established on January 5, 2026, with a registered capital of 5 million RMB and is located in Changsha City [1] - The company is involved in various sectors including the production and operation of medical devices, drug import and export, and research and development in cell technology and human stem cell technology [1] Group 2 - The company is authorized to engage in the production of second and third-class medical devices, as well as the rental and sale of medical equipment [1] - It also focuses on technology services, development, consultation, and the sale of hygiene products and disposable medical supplies [1] - The business activities are subject to approval by relevant authorities, and specific operations will commence only after obtaining the necessary permits [1]

基金的募资规模暂定为5亿元，其中公司作为有限合伙人拟以自有资金认缴出资不超过1亿元，约占基金 募资规模的20%。 近日，和元生物发布公告称，公司拟参与设立产业并购基金，基金名称为和元弘盛产业投资基金合伙企 业，主要投资于细胞与基因治疗产业链及其上下游相关行业。 ...

| | | 上海和元生物技术（集团）股份有限公司 章 程 二〇二六年二月 | 第十章 | 修改章程 - | 47 | - | | --- | --- | --- | --- | | 第十一章 | 信息披露与股东关系管理 - | 48 | - | | 第十二章 | 争议解决 - | 48 | - | 上海和元生物技术（集团）股份有限公司 章程 第一章 总 则 第一条 为了维护上海和元生物技术（集团）股份有限公司（以下简称"公司" 或"本公司"）、股东、职工和债权人的合法权益，规范公司的组织和行为，根 据《中华人民共和国公司法》（以下简称"《公司法》"）和其他相关法律、行 政法规和规范性文件有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司，采取发 起设立方式，由和元生物技术（上海）有限公司按原账面净资产值折股整体变更 设立的股份有限公司，在上海市市场监督管理局注册登记，取得营业执照。统一 社会信用代码为 913100000625940784。 | 第一章 | 总 则 - | 4 | - | | --- | --- | --- | --- | | 第二章 | 经营宗旨和范围 - ...

证券代码：688238 证券简称：和元生物 公告编号：2026-003 （二）变更原因 公司自 2013 年成立以来，以"赋能细胞基因治疗，共守生命健康"为使命， 深耕细胞和基因治疗核心领域并不断扩展产业链，致力打造成为以细胞和基因治 1 疗为核心的国际化产业集团，推动细胞和基因治疗及相关健康产业的技术开发及 转化应用，造福生命健康。目前公司主营业务已覆盖为细胞和基因治疗的基础研 究提供基因治疗载体研制、基因功能研究、药物靶点及药效研究等 CRO 服务；为 细胞与基因治疗药物的研发提供工艺开发及测试、IND-CMC 药学研究、临床样品 及商业化产品的 GMP 生产等 CDMO 服务；为再生医学及抗衰领域提供细胞制备、 重组蛋白/外泌体等细胞衍生物生产、细胞存储等技术服务三大板块。 和元生物技术（上海）股份有限公司 关于变更公司名称、修订《公司章程》并办理工商变 更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 和元生物技术（上海）股份有限公司（以下简称"公司"）于 2026 年 2 月 4 日召开了第四届董事会 ...

证券代码：688238 证券简称：和元生物 公告编号：2026-002 和元生物技术（上海）股份有限公司 关于参与设立产业并购基金暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 产业并购基金名称及投资方向：和元弘盛产业投资基金合伙企业（有限 合伙）（暂定名，以下简称"产业并购基金"或"基金"，以企业登记机关最终核 准登记为准），该基金根据国家生物医药发展战略及上海先导产业发展战略，将 主要定位在细胞与基因治疗产业链及其上下游相关行业的并购与投资。 1 确定性； 2）基金具有投资周期长、流动性较低等特点，就本次投资，公司将面临较 长的投资回收期，并且基金在投资过程中将受宏观经济、监管政策、投资标的经 营管理、交易方案、投后管理等多种因素影响，因此本次投资对公司未来财务状 况及经营成果的影响存在不确定性，可能存在投资收益不及预期的风险； 3）基金其他合伙人尚未完全确定，最终产业并购基金募资规模金额存在不 确定性。 一、参与产业并购基金暨关联交易概述 拟投资金额、在基金中的占比：产业并购基金募资规模 ...